P5-13-16: Reduction in PET Uptake-Value Is an Early Predictor for Response to Neoadjuvant Therapy Including Anthracycline and Taxane in Stage II-IIIa Breast

Autor:	MA Ubieto, Hernandez T Puértolas, de Miguel A Cebollero, Molias A Godoy, Torres A Anton, Perez J Madani, Mur C Garcia, Cortes A Artal, Romera J Lao, Alejandro M Alvarez
Rok vydání:	2011
Předmět:	Cancer Research medicine.medical_specialty Taxane Anthracycline business.industry medicine.medical_treatment Cancer Induction chemotherapy medicine.disease Gastroenterology Primary tumor Surgery Breast cancer Oncology Internal medicine medicine Stage (cooking) business Neoadjuvant therapy
Zdroj:	Cancer Research. 71:P5-13
ISSN:	1538-7445 0008-5472
DOI:	10.1158/0008-5472.sabcs11-p5-13-16
Popis:	Background and Aim: Reduction in FDG-PET uptake as response predictor after induction chemotherapy for breast cancer has been described. Our aim was to determine whether a SUV reduction ≥45% in the breast lesion could accurately predict pathological Complete Response (pCR). Material and Method: Stage II-IIIa breast cancer patients (p) with primary tumor ≥3cm or positive axilla were included provided they were amenable to neoadjuvant chemotherapy with Docetaxel-Doxorubicin-Cyclophosphamide (TAC). A FDG-PET scan was performed on day −1 of the first course and was repeated on day+8 of the same course. SUV-uptake differences (day 8 minus day −1) were correlated to the eventual pathological response according to Miller-Payne criteria. Results: 42p were included. Median age was 45 years (30-66). 11p (26.2%) were triple-negative tumors. 2p (4.8%) were Her-2 +. By stage, 13p (30.9%) were IIA, 17p (40.4%) IIB and 12p (28.2%) IIIA. 23p (54.7%) were N+ (FNAB positive). Median breast-SUV on first PET scan was 5.51 (1.3−18.50). 40p (95.2 %) completed the scheduled 6 courses. 41p (97.6%) were submitted to surgery. 11p (26.2%) achieved a pCR. 40p (95.2%) were evaluable for the primary objective. 1p (0.02%) died of disease progression before surgery and 1p (0.02%) with pCR could not be assessed by PET. 7 out of 14 p (50%) with uptake reduction ≥45% with respect to the basal value, and 3/26p (11.5%) whose reduction was 45% accurately predicted 7/10 pCR (70%) that could be assessed. Conclusions: Our study confirmed the value of PET-SUV reduction on day 8th as an early predictor of pCR with neoadjuvant TAC chemotherapy. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-13-16.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::679dc4001016a792e9cc95a6a762befe https://doi.org/10.1158/0008-5472.sabcs11-p5-13-16 Zobrazit plný text záznamu